Literature DB >> 7671999

Sigma binding site ligands inhibit cell proliferation in mammary and colon carcinoma cell lines and melanoma cells in culture.

P J Brent1, G T Pang.   

Abstract

Recent evidence suggests a role for sigma (sigma) binding sites in maintenance of cell growth and/or proliferation. The present study examines, for the first time, the effect of sigma binding site ligands on in vitro growth of tumour cells derived from human mammary adenocarcinoma (MCF-7, MDA) and colon carcinoma (LIM 1215, WIDr), and melanoma (Chinnery). Addition of the sigma ligands haloperidol, reduced haloperidol, 1,3-di(2-tolyl)guanidine (DTG), (+)- and (-)-N-allylnormetazocine (SKF 10,047), (+)- and (-)-pentazocine and rimcazole at 6.25, 12.5, 25, 50, 100 microM at the beginning of culture or 24 h later, inhibited cell proliferation in a dose-dependent manner. Light microscopy revealed cell detachment, rounding and cell death. The potency of sigma ligands on melanoma cells was rimcazole > reduced haloperidol > haloperidol = (+)-pentazocine, whereas DTG and (+)- and (-)-SKF 10,047 and (-)-pentazocine had no effect even at 100 microM. In contrast, in MCF-7 cells, rimcazole > reduced haloperidol > haloperidol > (-)-pentazocine > DTG > (+)-pentazocine > (+)-SKF 10,047 > (-)-SKF 10,047. For colon cancer cells, reduced haloperidol > DTG > haloperidol = (-)-pentazocine = (+)-pentazocine = (+)-SKF 10,047. Of all the ligands tested, rimcazole and reduced haloperidol were the most potent inhibitors of cell proliferation. With the exception of one slow-growing colon cancer cell line (LIM 1215), the order of sensitivity of various cell lines to reduced haloperidol, SFK 10,047, DTG, haloperidol and (+)- and (-)-pentazocine was colon carcinoma > mammary adenocarcinoma > melanoma, whereas to rimcazole, the sensitivities of mammary adenocarcinoma and melanoma cells were comparable. The effect of sigma ligands in MCF-7 and melanoma cells was not due to blockade of dopamine D1 and D2 receptors, serotonin (5-HT2) receptors, N-methyl-D-aspartate (NMDA)/phencyclidine receptors, beta-adrenoceptors or opioid receptors, since 100 microM SCH 23390, raclopride, mianserin, (+)-MK-801, propranolol and 1 microM naloxone respectively, were ineffective. However, mianserin and raclopride were inhibitory to melanoma cells and one colon carcinoma cell line, respectively. Taken together, the results are consistent with the recent observation that sigma binding sites may play a role in cell growth and/or cell proliferation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7671999     DOI: 10.1016/0014-2999(95)00115-2

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  16 in total

1.  Overexpression of sigma-1 receptor in MCF-7 cells enhances proliferation via the classic protein kinase C subtype signaling pathway.

Authors:  Yuqi Wu; Xueyan Bai; Xiaoyang Li; Chang Zhu; Zachary P Wu
Journal:  Oncol Lett       Date:  2018-09-18       Impact factor: 2.967

2.  Antagonists show GTP-sensitive high-affinity binding to the sigma-1 receptor.

Authors:  J M Brimson; C A Brown; S T Safrany
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

3.  Synthesis and in vitro biological evaluation of carbonyl group-containing analogues for σ1 receptors.

Authors:  Wei Wang; Jinquan Cui; Xiaoxia Lu; Prashanth K Padakanti; Jinbin Xu; Stanley M Parsons; Robert R Luedtke; Nigam P Rath; Zhude Tu
Journal:  J Med Chem       Date:  2011-07-20       Impact factor: 7.446

4.  Sigma receptors [σRs]: biology in normal and diseased states.

Authors:  Colin G Rousseaux; Stephanie F Greene
Journal:  J Recept Signal Transduct Res       Date:  2015-06-09       Impact factor: 2.092

5.  Effects of sigma ligands on the cloned mu-, delta- and kappa-opioid receptors co-expressed with G-protein-activated K+ (GIRK) channel in Xenopus oocytes.

Authors:  T Kobayashi; K Ikeda; T Ichikawa; S Togashi; T Kumanishi
Journal:  Br J Pharmacol       Date:  1996-09       Impact factor: 8.739

6.  Overexpression of sigma1 receptor and its positive associations with pathologic TNM classification in esophageal squamous cell carcinoma.

Authors:  Qing-Xia Xu; En-Min Li; Yong-Fa Zhang; Lian-Di Liao; Xiu-E Xu; Zhi-Yong Wu; Jin-Hui Shen; Li-Yan Xu
Journal:  J Histochem Cytochem       Date:  2012-04-17       Impact factor: 2.479

7.  Acute effects of the sigma-2 receptor agonist siramesine on lysosomal and extra-lysosomal proteolytic systems in lens epithelial cells.

Authors:  S Jonhede; A Petersen; M Zetterberg; J-O Karlsson
Journal:  Mol Vis       Date:  2010-05-08       Impact factor: 2.367

8.  4-IBP, a sigma1 receptor agonist, decreases the migration of human cancer cells, including glioblastoma cells, in vitro and sensitizes them in vitro and in vivo to cytotoxic insults of proapoptotic and proautophagic drugs.

Authors:  Véronique Mégalizzi; Véronique Mathieu; Tatjana Mijatovic; Philippe Gailly; Olivier Debeir; Nancy De Neve; Marc Van Damme; Gianluca Bontempi; Benjamin Haibe-Kains; Christine Decaestecker; Yasuko Kondo; Robert Kiss; Florence Lefranc
Journal:  Neoplasia       Date:  2007-05       Impact factor: 5.715

9.  Synthesis and characterization of N,N-dialkyl and N-alkyl-N-aralkyl fenpropimorph-derived compounds as high affinity ligands for sigma receptors.

Authors:  Abdol R Hajipour; Dominique Fontanilla; Uyen B Chu; Marty Arbabian; Arnold E Ruoho
Journal:  Bioorg Med Chem       Date:  2010-04-29       Impact factor: 3.641

10.  Melanoma-associated Chondroitin Sulfate Proteoglycan (MCSP)-targeted delivery of soluble TRAIL potently inhibits melanoma outgrowth in vitro and in vivo.

Authors:  Marco de Bruyn; Anna A Rybczynska; Yunwei Wei; Michael Schwenkert; Georg H Fey; Rudi A J O Dierckx; Aren van Waarde; Wijnand Helfrich; Edwin Bremer
Journal:  Mol Cancer       Date:  2010-11-23       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.